Referring to our online pharmaceutical pipeline database
http://www.chartsbank.com/PipelineList.aspx
we were also engaged by a major pharmaceutical company to perform a full portfolio assessment of their product pipeline and help the company pursue potential licensing agreements in order to realize its 5 to 10 year earnings aspirations.
Phase 1:
The first step was to quickly identify the most attractive and available compounds, or drugs in development, that would be good candidates for developing the portfolio. Working closely with the client, Bulresearch team scanned a vast library of pipeline compounds, fully assessing the profitability of various therapeutic areas and disease states, trends in populations, unmet medical need, and strategic fit. The team also tapped not only the client's knowledge and experience but also that of Bulresearch and external experts worldwide. As a result of this intensive analysis, the team quickly narrowed 1,200 potential leads to 18 priority compounds, and finally, to 6 viable licensing candidates.
Phase 2:
Bulresearch team then helped the client pursue these deals. We worked with the client to develop a clear assessment plan for meeting with licensing candidates and coached the client through multiple rounds of negotiations. By helping the client maintain focus, momentum, and objectivity, the Bulresearch team provided both tactical and strategic support.
Phase 3:
As a final phase to this engagement, the Bulresearch team provided additional insights beyond the central objective by working with the client to identify potential revenue gaps and establish strategic priorities. Further, it helped define performance improvements required to boost sales and set specific operating targets to help the client track outcomes.
Monday, May 15, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment